Abstract:Objective:Despite the success of docetaxel as an anti-tumor agent,the inter-individual variability in drug response still poses a major impediment on further use of this agent in the treatment of cancer.As some patients are inherent or acquired-resistance to this drug,biomarkers are desired to stratify patients into groups of different likelihood of the tumor response before chemotherapy,thus maximizing effects and minimizing toxicities of chemotherapy.Our current study focus on two promising biomarkers,BRCA1(breast cancer susceptibility gene 1) and β-tubulin Ⅲ.To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases,we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with docetaxel sensitivity.Methods: Real-time quantitative PCR was used to test related genes expression in forty-one malignant effusions prospectively collected.Viable tumor cells obtained from malignant effusions were tested for sensitivity to docetaxel using ATP-TCA assay.Results: BRCA1 expression level was positively correlated with sensitivity to docetaxel in non small cell lung cancer(NSCLC)(P=0.008) and gastric cancer patients(P=0.032),meanwhile β-tubulin Ⅲ expression level was inversely correlated with sensitivity to doxetaxel in malignant effusions of NSCLC patients(P=0.022).No significant interaction was found between BRCA1 and β-tubulin Ⅲ mRNA expressions on sensitivity to docetaxel(P0.05).Conclusion: Our results demonstrated that BRCA1 and β-tubulin III mRNA expression level in malignant effusions,in which all cancer cells were metastatic,were correlated with docetaxel sensitivity.Meanwhile,BRCA1 may be a better predictive marker for chemosensitivity to doxetaxel than β-tubulin Ⅲ.At the cost of a centesis,it may be possible to acquire a limited genomic portrait of tumor in some patients with malignant effusions,enabling the development of real-time individualized chemotherapy while tumor progression.

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

Relationship Between Plasma BRCA1 Mrna Expression and Sensitivity to Docetaxel and Cisplatin in Gastric Cancer.

Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced NSCLC Patients Treated with Cisplatin-Based Chemotherapy

BRCA1 Mrna Expression As a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy

The Effects of ERCC1 Expression Levels on the Chemosensitivity of Gastric Cancer Cells to Platinum Agents and Survival in Gastric Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

Expression of Ercc1, Bcl-2, Mt and Their Clinical Significance in Advanced Non-Small-Cell Lung Cancer Treated with Cisplatin-Based Chemotherapy

ERCC1 and BRCA1 Expressions in the Tissues of Colorectal Cancer and Its Relationship with Clinical Significance of Platinum-Based Chemotherapy

Detection of Cell-Free ERCC1 and Thymidylate Synthase (TS) Mrna in Malignant Effusions and Its Association with Anticancer Drug Sensitivity.

Positive Expression of ERCC1 Predicts a Poorer Platinum-Based Treatment Outcome in Chinese Patients with Advanced Non-Small-cell Lung Cancer